Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710171 | 0.92 | CTSK (0.39) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL3878001 | 0.89 | CTSK (0.35) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL3128871 | 0.84 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL3548228 | 0.84 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL3388039 | 0.81 | PDE4B (0.49) | CTSKHSD11B1CYP2C9MEN1KMT2A | |
| SCHEMBL3388042 | 0.81 | PDE4B (0.49) | CTSKHSD11B1CYP2C9MEN1KMT2A | |
| SCHEMBL11978250 | 0.81 | PDE4B (0.49) | CTSKHSD11B1CYP2C9MEN1KMT2A | |
| SCHEMBL13740513 | 0.79 | PPM1D (0.32) | — | |
| SCHEMBL15913901 | 0.79 | PPM1D (0.32) | — | |
| SCHEMBL15121817 | 0.79 | TSHR (0.37) | CTSKCA1CA2HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9556178-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-21 | — | — | US | disclosed |
| US-9273057-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| US-20150065465-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-05 | — | — | US | disclosed |
| US-8940736-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-16 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | CTSK 2008/4885CA1 3557/4885CA2 897/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CTSK 2489/4885CA1 3450/4885CA2 2979/4885 |
| US-20150065465-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | CTSK 2008/4885CA1 3557/4885CA2 897/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CTSK 2489/4885CA1 3450/4885CA2 2979/4885 |
| US-20150210697-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | CTSK 2008/4885CA1 3557/4885CA2 897/4885 |
| US-20160108050-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | CTSK 2008/4885CA1 3557/4885CA2 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.